Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

Save

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article

2021 Rheumatology Year in Review

Save

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article

New Onset Rheumatic Disorders with COVID-19 Infection

Save

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Read Article

Best of 2021: Avacopan - Is it Really a Win for ANCA-Associated Vasculitis? The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with ANCA-AAV. https://t.co/cm9PX66zE7 https://t.co/e7S5C6eugK

NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/DDgu0UpZN9 https://t.co/BPlIEmRjg3

Genes and Obesity Tied to Higher Gout Risk in Women Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU

ICYMI: Giant Cell Arteritis Novel Treatment Options https://t.co/ywqGZNmHOa https://t.co/2hLESL1RjO

Giant Cell Arteritis Novel Treatment Options

Save

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

Read Article

FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m

Top vasculitis takeaways from ACR 2021

Save

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article

In case you missed it… Watch: What's Cool and Hot in Vasculitis with Dr. Janet Pope (@Janetbirdope ) #ACR21https://t.co/JbhQWeejy7 https://t.co/qlCCk3MXKu

Day 4 Report from ACR21

Save

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article

📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis #ACR21 https://t.co/Bdz5t2uyHi

#ACR21 #ACR2021 Clinical Pearls 🚨 Thread Alert 1/n 💥AAV does not typically cause hard palate lesions➡️consider: Cocaine induced midline destructive lesion(HNE+)/Malignancy 💥Limited GPA can be ANCA negetive in 50% 💥 oral cavity examination is a must in Rheum https://t.co/RxkLiGdcJt

#ACR21 TM24. Hydralazine-induced ANCA vasculitis presenting with chondritis. Labs: +ANA +Anti-histone +p-ANCA, +MPO and +PR3 @Rheumnow https://t.co/YQvqj0vCHp https://t.co/LPyVYYzLtI

#ACR21 2022 ACR/EULAR GPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical, lab, imaging, and biopsy criteria ⭐️+5 pts for cANCA or PR3, negative pts for pANCA or MPO, or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/vg8zaFt5dR

ACR/EULAR Classification Criteria for ANCA vasculitis, updated from prior Similar disclaimer; these are for use AFTER the diagnosis of small or medium vasculitis has been made Great international effort, kudos to all involved #ACR21 #ACRambassador https://t.co/a29TVvzVF7